Raymond Thertulien

2.0k total citations · 1 hit paper
33 papers, 1.4k citations indexed

About

Raymond Thertulien is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Raymond Thertulien has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 13 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Raymond Thertulien's work include Multiple Myeloma Research and Treatments (18 papers), Cancer Treatment and Pharmacology (7 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Raymond Thertulien is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), Cancer Treatment and Pharmacology (7 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Raymond Thertulien collaborates with scholars based in United States, Italy and United Kingdom. Raymond Thertulien's co-authors include Bart Barlogie, Athanasios Fassas, Frits van Rhee, Guido Tricot, Maurizio Zangari, Giampaolo Talamo, Elias Anaissie, Klaus Hollmig, Erik Rasmussen and John Crowley and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Raymond Thertulien

32 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

2006 532 citations Bart Barlogie, Guido Tricot et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raymond Thertulien United States	15	1.1k	706	562	250	141	33	1.4k
Wim Terpstra Netherlands	18	542 0.5×	317 0.4×	276 0.5×	183 0.7×	115 0.8×	36	1.0k
Rudolf Pihusch Germany	21	685 0.6×	253 0.4×	211 0.4×	141 0.6×	154 1.1×	43	1.2k
Stephen Caplan Canada	15	320 0.3×	370 0.5×	159 0.3×	151 0.6×	51 0.4×	34	898
C. Tom Kouroukis Canada	18	383 0.4×	252 0.4×	460 0.8×	346 1.4×	62 0.4×	49	1.2k
Nicholas Wickham Australia	16	292 0.3×	256 0.4×	130 0.2×	174 0.7×	95 0.7×	35	804
Yeo‐Kyeoung Kim South Korea	20	675 0.6×	412 0.6×	261 0.5×	253 1.0×	21 0.1×	91	1.2k
Saskia K. Klein Netherlands	14	434 0.4×	248 0.4×	224 0.4×	130 0.5×	32 0.2×	43	919
Peter A.W. te Boekhorst Netherlands	21	582 0.5×	221 0.3×	263 0.5×	245 1.0×	22 0.2×	50	1.1k
Joan J. Ryoo United States	10	572 0.5×	476 0.7×	427 0.8×	107 0.4×	14 0.1×	19	872
C.J. Cornell United States	11	335 0.3×	233 0.3×	175 0.3×	124 0.5×	242 1.7×	19	842

Countries citing papers authored by Raymond Thertulien

Since Specialization

Citations

This map shows the geographic impact of Raymond Thertulien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond Thertulien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond Thertulien more than expected).

Fields of papers citing papers by Raymond Thertulien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond Thertulien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond Thertulien. The network helps show where Raymond Thertulien may publish in the future.

Co-authorship network of co-authors of Raymond Thertulien

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond Thertulien. A scholar is included among the top collaborators of Raymond Thertulien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond Thertulien. Raymond Thertulien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goss, Glenwood, Ravi Salgia, Benjamin Besse, et al.. (2011). Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(8). 1418–1425. 54 indexed citations

Araten, David J., Rosario Notaro, Howard T. Thaler, et al.. (2011). Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. Haematologica. 97(3). 344–352. 20 indexed citations

Philpot, Lindsey M., Rohit P. Ojha, Martha Felini, et al.. (2011). Site-specific relative risks of second primary malignancies among patients with Waldenstrom macroglobulinemia.. Journal of Clinical Oncology. 29(15_suppl). e18566–e18566. 1 indexed citations

Thertulien, Raymond, G. Manikhas, Luc Dirix, et al.. (2011). Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 69(2). 341–350. 7 indexed citations

Ojha, Rohit P., et al.. (2010). The association between renal cell carcinoma and multiple myeloma: insights from population‐based data. British Journal of Urology. 108(6). 825–830. 15 indexed citations

Ojha, Rohit P., Lori Fischbach, Yi Zhou, et al.. (2010). Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma. Cancer Epidemiology. 34(3). 274–278. 24 indexed citations

Thertulien, Raymond, Arthur E. Frankel, Andrew M. Evens, et al.. (2009). Abstract #1227: A phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin\#8217;s lymphoma. Cancer Research. 69. 1227–1227. 10 indexed citations

Zangari, Maurizio, Athanasios Fassas, Raymond Thertulien, et al.. (2006). Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplantation. 37(5). 511–515. 3 indexed citations

Miceli, Marisa H., Dong Lei, Monica Grazziutti, et al.. (2006). Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplantation. 37(9). 857–864. 87 indexed citations

10.

Ojha, Rohit P. & Raymond Thertulien. (2005). Health Care Policy Issues as a Result of the Genetic Revolution: Implications for Public Health. American Journal of Public Health. 95(3). 385–388. 11 indexed citations

11.

Tricot, Guido, John Crowley, Athanasios Fassas, et al.. (2004). Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).. Blood. 104(11). 936–936. 2 indexed citations

12.

Hollmig, Klaus, Maurizio Zangari, Raymond Thertulien, et al.. (2004). Addition of Bortezomib (Velcade™) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).. Blood. 104(11). 929–929. 20 indexed citations

13.

Lee, CK, Maurizio Zangari, Bart Barlogie, et al.. (2004). Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplantation. 33(8). 823–828. 83 indexed citations

14.

Anaissie, E., Joth Jacobson, Athanasios Fassas, et al.. (2003). Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. Blood. 102(11). 1 indexed citations

15.

Zangari, Maurizio, Bart Barlogie, Raymond Thertulien, et al.. (2003). Thalidomide and Deep Vein Thrombosis in Multiple Myeloma: Risk Factors and Effect on Survival. Clinical Lymphoma. 4(1). 32–35. 86 indexed citations

16.

Badros, Ashraf, Bart Barlogie, Christopher Morris, et al.. (2003). Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Experimental Hematology. 31(1). 73–80. 71 indexed citations

17.

Fassas, Athanasios, Bart Barlogie, Susan Ward, et al.. (2003). Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. British Journal of Haematology. 123(3). 484–489. 11 indexed citations

18.

Barlogie, Bart, Maurizio Zangari, Athanasios Fassas, et al.. (2002). Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplantation. 30(12). 873–878. 31 indexed citations

19.

Karadimitris, Anastasios, Ke Li, Rosario Notaro, et al.. (2001). Association of clonal T‐cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH. British Journal of Haematology. 115(4). 1010–1014. 41 indexed citations

20.

Thertulien, Raymond, Patricia J. Simpson‐Haidaris, & Constantine G. Haidaris. (1994). Intracellular Localization of a Trypanosoma cruzi kDNA Minicircle Transcript Using RNA: RNA In Situ Hybridization. Journal of Eukaryotic Microbiology. 41(4). 402–407. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact